Expanding PrEP Implementation in Communities of People Who Inject Drugs and Their Risk Network Members
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- HIV
- Sponsor
- University of Connecticut
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Retention Rate
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This non-randomized, open-label study will address the following research aims in People who inject drugs (PWID):
- To assess the feasibility and acceptability of the Expanding PrEP Implementation in Communities of PWID (EPIC-P) intervention among high-risk PWID.
- To determine the preliminary efficacy of the EPIC-P intervention in terms of increasing adherence to PrEP and primary HIV prevention among high-risk PWID.
Detailed Description
A non-randomized, open-label design will be utilized to test the feasibility, acceptability, and preliminary efficacy of the Expanding PrEP Implementation in Communities of PWID (EPIC-P) intervention among high-risk people who inject drugs (PWID) with opioid dependence (N=100). Since the aim of this pilot study is to establish whether the EPIC-P intervention is feasible/acceptable among at-risk PWID in a community-based setting, proposed is a non-comparative design. With the hopes to target PWID who are not linked with existing harm reduction services, proposed is to recruit participants using respondent driven sampling (RDS), a chain referral method with demonstrated success in recruiting hard-to-reach populations. Initial RDS participants, called "seeds," will be carefully recruited from the community where the study team leadership have built a well-established relationship. Participants enrolled in the study will be assessed at baseline and will be followed for 9 months (with follow-up assessments at 3- and 6-months) by trained research assistants. Importantly, structured interviews will be conducted at follow-up visits to examine the barriers and facilitators and feedback about optimal implementation of the EPIC-P intervention.
Investigators
Roman Shrestha
Assistant Professor
University of Connecticut
Eligibility Criteria
Inclusion Criteria
- •Residing in the Greater New Haven area;
- •Confirmed HIV-negative;
- •Reporting injection drug use (past 3 months) with substantial ongoing risk for HIV acquisition;
- •Started on PrEP (within the last week).
Exclusion Criteria
- •Not on PrEP;
- •Not available during the full duration of the study;
- •Cannot speak English;
- •Unable to provide consent;
- •Anyone actively suicidal, homicidal, or psychotic as assessed by trained research staff under the supervision of a consultant that is a licensed clinical psychologist.
Outcomes
Primary Outcomes
Retention Rate
Time Frame: Up to 6 months
To determine feasibility, the rate of enrolled participants that are retained through the study will be assessed.
Secondary Outcomes
- PrEP Adherence VAS(Up to 6 months)
- PrEP Adherence DBS(Up to 6 months)
- PrEP Adherence Pharmacy(Up to 6 months)
- Acceptability(Up to 6 months)
- HIV Incidence(Up to 6 months)